Demographics of the study population (n = 831)
| Characteristics . | No. of patients (%) . |
|---|---|
| HLA-A, -B serologic matches | 696 (84) |
| T-cell depleted | 177 (21) |
| Year of transplantation | |
| 1988-1989 | 73 (9) |
| 1990-1993 | 383 (46) |
| 1994-1997 | 375 (45) |
| First chronic phase | 578 (70) |
| Accelerated phase | 189 (23) |
| Second chronic phase | 64 (8) |
| Gender (recipient–donor) | |
| Female/female | 171 (21) |
| Female/male | 176 (21) |
| Male/female | 187 (23) |
| Male/male | 297 (36) |
| Conditioning regimen | |
| Cy + TBI | 458 (55) |
| Cy + TBI + other | 246 (30) |
| Cy + Bu | 102 (12) |
| Other combination | 25 (3) |
| Recipient CMV status at transplantation | |
| Positive | 401 (48) |
| Negative | 425 (51) |
| Missing/undetermined | 5 (1) |
| Characteristics . | No. of patients (%) . |
|---|---|
| HLA-A, -B serologic matches | 696 (84) |
| T-cell depleted | 177 (21) |
| Year of transplantation | |
| 1988-1989 | 73 (9) |
| 1990-1993 | 383 (46) |
| 1994-1997 | 375 (45) |
| First chronic phase | 578 (70) |
| Accelerated phase | 189 (23) |
| Second chronic phase | 64 (8) |
| Gender (recipient–donor) | |
| Female/female | 171 (21) |
| Female/male | 176 (21) |
| Male/female | 187 (23) |
| Male/male | 297 (36) |
| Conditioning regimen | |
| Cy + TBI | 458 (55) |
| Cy + TBI + other | 246 (30) |
| Cy + Bu | 102 (12) |
| Other combination | 25 (3) |
| Recipient CMV status at transplantation | |
| Positive | 401 (48) |
| Negative | 425 (51) |
| Missing/undetermined | 5 (1) |
Categories are based on combinations of Cy, TBI, VP16, BU, Ara-C, ALG, and Thiotepa. In some patients, other drugs were also used but were ignored for purposes of this classification.
The median recipient age was 35 years (range, 2-63 years). The median donor age was 38 years (range, 18-56 years). The median disease duration was 1.4 years (range, 0.2-18.2 years); the diagnosis date was missing for 2 cases.
Cy indicates cyclophosphamide; TBI, total body irradiation; Bu, busulfan; ALG, antilymphocyte globulin.